The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global brachytherapy market reached a value of US$ 785 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,033.9 Million by 2027, exhibiting a CAGR of 5.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Brachytherapy, also known as internal radiation therapy, is a form of radiotherapy in which radiation is transported directly through a source implanted near or next to the cancerous tumor in the body. The source produces gamma rays that are focused on cancer cells and reduce the damage to surrounding healthy tissue. Brachytherapy is either administered in Low Dose Rate (LDR) or High Dose Rate (HDR) depending upon the severity of the disease and its damage. For LDR, small radioactive seeds are implanted permanently in or around the tumor, whereas, for HDR, radioactive sources are removed from the patient’s body at the termination of each session and is used in the cases of high-risk cancers.
The rising prevalence of different types of cancer is one of the key factors driving the global market. Brachytherapy has been proven to be an extremely effective treatment option for cervical, skin and breast cancers, which is contributing significantly to its market growth. Furthermore, the availability of high-quality brachytherapy equipment that provides accurate and extremely localized doses of radiation to small tumors has enhanced the acceptance of the therapy amongst patients and medical professionals alike. Technological advancements in oncology treatments and extensive research and development (R&D), such as trials for treating neovascular age-related macular degeneration, have also provided a significant boost to the market growth. In addition to this, growing medical tourism across the globe, along with increasing awareness about the advantages of brachytherapy and its cost-effectiveness and increasing cure rate as compared to surgery or external beam therapy (EBT), is also significantly driving the market.
IMARC Group’s latest report provides a deep insight into the global brachytherapy market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global brachytherapy market in any manner.
IMARC Group provides an analysis of the key trends in each sub-segment of the global brachytherapy market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on service type, technology, mode of procurement and end-user.
Breakup by Service Type:
Breakup by Technology:
Breakup by Mode of Procurement:
Breakup by End-User:
Breakup by Region:
The report has also analyzed the competitive landscape of the market with some of the key players being Acusis Software India Pvt Ltd., Transcend Services, Inc., Naunce Communications, Inc., MModal Global Services Pvt. Ltd., iMedX Information Services Pvt. Ltd., Global Medical Transcription LLC, nThrive Solutions LLC, MTBC (CareCloud, Inc.), Medi-Script Plus and Transtech Medical Solutions LLC, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Service Type, Technology, Mode of Procurement, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Acusis Software India Pvt Ltd., Transcend Services, Inc., Naunce Communications, Inc., MModal Global Services Pvt. Ltd., iMedX Information Services Pvt. Ltd., Global Medical Transcription LLC, nThrive Solutions LLC, MTBC (CareCloud, Inc.), Medi-Script Plus and Transtech Medical Solutions LLC|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global brachytherapy market was valued at US$ 785 Million in 2021.
We expect the global brachytherapy market to exhibit a CAGR of 5.2% during 2022-2027.
The high prevalence of cervical, skin, and breast cancers, along with increasing adoption of brachytherapy among doctors for delivering higher doses of radiation to specific body parts, is primarily driving the global brachytherapy market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective brachytherapy procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment.
Based on the end user, the global brachytherapy market can be bifurcated into hospitals, clinics, clinical laboratories, academic medical centers, and others. Currently, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global brachytherapy market include Acusis Software India Pvt Ltd., Transcend Services, Inc., Naunce Communications, Inc., MModal Global Services Pvt. Ltd., iMedX Information Services Pvt. Ltd., Global Medical Transcription LLC, nThrive Solutions LLC, MTBC (CareCloud, Inc.), Medi-Script Plus, Transtech Medical Solutions LLC, etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at